{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:24:49Z","timestamp":1792801489547,"version":"4.5.0"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tuberculosis (TB) remains a serious public health threat around the world. An effective vaccine is urgently required for cost-effective, long-term control of TB. However, the only licensed vaccine Bacillus Calmette-Guerin (BCG) is limited to prevent TB for its highly variable efficacy. Substantial progress has been made in research and development (R&amp;amp;D) of TB vaccines in the past decades, and a dozen vaccine candidates, including live attenuated mycobacterial vaccines, killed mycobacterial vaccines, adjuvanted subunit vaccines, viral vector vaccines, and messenger RNA (mRNA) vaccines were developed in clinical trials to date. Nevertheless, many challenges to the successful authorization for the use and deployment of an effective tuberculosis vaccine remain. Therefore, it is still necessary and urgent to continue exploring new vaccine construction approaches. Virus-like particles (VLPs) present excellent prospects in the field of vaccine development because of their helpful immunological features such as being safe templates without containing viral nucleic acid, repetitive surface geometry, conformational epitopes similar to natural viruses, and enhancing both innate and adaptive immune responses. The marketization process of VLP vaccines has never stopped despite VLP vaccines face several shortcomings such as their complex and slow development process and high production cost, and several VLP-based vaccines, including vaccines against Human papillomavirus (HPV), Hepatitis B Virus (HBV) and malaria, are successfully licensed for use at the market. In this review, we provide an update on the current progress regarding the development of TB vaccines in clinical trials and seek to give an overview of VLP-based TB vaccine candidates.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1238649","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:08:06Z","timestamp":1698944886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates"],"prefix":"10.3389","volume":"14","author":[{"given":"Fangbin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02756-2","article-title":"Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria","volume":"399","author":"Hosseinpoor","year":"2022","journal-title":"Lancet"},{"key":"B2","volume-title":"Global tubeculosis report 2022","year":"2022"},{"key":"B3","unstructured":"2023"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30625-5","article-title":"The status of tuberculosis vaccine development","volume":"20","author":"Schrager","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005271","article-title":"Tuberculosis in newborns: the lessons of the \"L\u00fcbeck\u00a0disaster\" (1929-1933)","volume":"12","author":"Fox","year":"2016","journal-title":"PloS Pathog"},{"key":"B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"105668","DOI":"10.1016\/j.antiviral.2023.105668","article-title":"Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice","volume":"216","author":"Xia","year":"2023","journal-title":"Antiviral Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s11427-023-2378-x","article-title":"Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1935328","article-title":"Where are the RNA vaccines for TB","volume":"10","author":"Fan","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2013.09.002","article-title":"Virus-like particle-based human vaccines: quality assessment based on structural and functional properties","volume":"31","author":"Zhao","year":"2013","journal-title":"Trends Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00807-7","article-title":"Implementation of the malaria candidate vaccine RTS,S\/AS01","volume":"387","author":"Greenwood","year":"2016","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0174-z","article-title":"Moving tuberculosis vaccines from theory to practice","volume":"19","author":"Andersen","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8533","DOI":"10.1038\/ncomms9533","article-title":"Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis","volume":"6","author":"Kaushal","year":"2015","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00324","article-title":"Functional, antigen-specific stem cell memory (T(SCM)) CD4(+) T cells are induced by human mycobacterium tuberculosis infection","volume":"9","author":"Mpande","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000392","article-title":"A critical role for CD8 T cells in a nonhuman primate model of tuberculosis","volume":"5","author":"Chen","year":"2009","journal-title":"PloS Pathog"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344358","article-title":"High-frequency vaccine-induced CD8+ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection","volume":"44","author":"Lindenstr\u00f8m","year":"2014","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444954","article-title":"Epitope-specific CD4+, but not CD8+, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection","volume":"45","author":"Fl\u00f3rido","year":"2015","journal-title":"Eur J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1585246","article-title":"Deciphering protective immunity against tuberculosis: implications for vaccine development","volume":"18","author":"Counoupas","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O'Garra","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0028-0","article-title":"Antibodies and tuberculosis: finally coming of age","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.04.004","article-title":"Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis","volume":"53","author":"Achkar","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A functional role for antibodies in tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1611776114","article-title":"Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0319-9","article-title":"Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques","volume":"25","author":"Dijkman","year":"2019","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00100-19","article-title":"Tuberculosis vaccine development: progress in clinical evaluation","volume":"33","author":"Sable","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1088\/0967-3334\/28\/1\/N01","article-title":"La vaccination pr\u00e9ventive contre la tuberculose par le BCG","volume":"34","author":"Echemendia","year":"1929","journal-title":"Microelectronics Reliabil"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy: from cattle to COVID-19","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technol Assess"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.17.2086","article-title":"Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study","volume":"291","author":"Aronson","year":"2004","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"Rodrigues","year":"2005","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","article-title":"Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1540_22","article-title":"Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease","volume":"157","author":"Velayutham","year":"2023","journal-title":"Indian J Med Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008356","article-title":"Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells","volume":"16","author":"Ahmad","year":"2020","journal-title":"PloS Pathog"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100313","article-title":"A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa","volume":"21","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130540","article-title":"BCG revaccination boosts adaptive polyfunctional Th1\/Th17 and innate effectors in IGRA+ and IGRA- Indian adults","volume":"4","author":"Rakshit","year":"2019","journal-title":"JCI Insight"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PloS Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30307-X","article-title":"Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling","volume":"19","author":"Knight","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.031","article-title":"BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay","volume":"27","author":"Eisenhut","year":"2009","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0026OC","article-title":"Identifying predictors of interferon-\u03b3 release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study","volume":"186","author":"Basu Roy","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205688","article-title":"The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland","volume":"69","author":"Michelsen","year":"2014","journal-title":"Thorax"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00839-5","article-title":"Protective effect of BCG and neutrophil-to-lymphocyte ratio on latent tuberculosis in end stage renal disease","volume":"12","author":"Wang","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis941","article-title":"Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns","volume":"207","author":"Soares","year":"2013","journal-title":"J Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113951","article-title":"Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice","volume":"9","author":"Nandakumar","year":"2014","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0714OC","article-title":"The influence of bacille calmette-guerin vaccine strain on the immune response against tuberculosis A randomized trial","volume":"185","author":"Ritz","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/mt.2015.216","article-title":"Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895020","article-title":"Research advances for virus-vectored tuberculosis vaccines and latest findings on tuberculosis vaccine development","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00222-5","article-title":"Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial","volume":"22","author":"Cotton","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41541-020-00262-8","article-title":"MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies","volume":"6","author":"White","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"Nell","year":"2014","journal-title":"PloS One"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: a new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"Cardona","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.003039","article-title":"Description of a novel species of fast growing mycobacterium: Mycobacterium kyogaense sp. nov., a scotochromogenic strain received as Mycobacterium vaccae","volume":"68","author":"Nouioui","year":"2018","journal-title":"Int J Syst Evol Microbiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175215","article-title":"Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901","volume":"12","author":"von Reyn","year":"2017","journal-title":"PloS One"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.055","article-title":"DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial","volume":"38","author":"Munseri","year":"2020","journal-title":"Vaccine"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/cells9122673","article-title":"Recent advances in the development of protein- and peptide-based subunit vaccines against tuberculosis","volume":"9","author":"Bellini","year":"2020","journal-title":"Cells"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201802-0366OC","article-title":"Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial","volume":"199","author":"Suliman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30319-2","article-title":"Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"9","author":"Day","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and Guinea pig TB models","volume":"12","author":"Tkachuk","year":"2017","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040166","article-title":"First-in-human trials of gamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment","volume":"7","author":"Vasina","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/vaccines8040652","article-title":"Safety and immunogenicity of the gamTBvac, the recombinant subunit tuberculosis vaccine candidate: A phase II, multi-center, double-blind, randomized, placebo-controlled study","volume":"8","author":"Tkachuk","year":"2020","journal-title":"Vaccines"},{"key":"B75","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","article-title":"Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects Guinea pigs in a model of latent infection","volume":"48","author":"Lu","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.3390\/vaccines10122164","article-title":"The subunit AEC\/BC02 vaccine combined with antibiotics provides protection in mycobacterium tuberculosis-infected Guinea pigs","volume":"10","author":"Guo","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"J Infect Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime \u2013 MVA85A boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.01.062","article-title":"A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults","volume":"34","author":"Minhinnick","year":"2016","journal-title":"Vaccine"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/infdis\/jiw467","article-title":"Induction of an immune-protective T-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans","volume":"214","author":"Jeyanathan","year":"2016","journal-title":"J Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1055\/a-1785-3936","article-title":"A new intranasal influenza vector-based vaccine TB\/FLU-04L against tuberculosis: preclinical safety studies","volume":"72","author":"Buzitskaya","year":"2022","journal-title":"Drug Res (Stuttg)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/vaccines9040394","article-title":"Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs","volume":"9","author":"Sergeeva","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111273","article-title":"Enhancement of the Local CD8+ T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens","volume":"9","author":"Vasilyev","year":"2021","journal-title":"Vaccines"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-coV-2 vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"JAMA J Am Med Assoc"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A Thermostable mRNA Vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","article-title":"Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus","volume":"8","author":"Sang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.11.6324-6329.2004","article-title":"RNA Encoding the MPT83 Antigen Induces Protective Immune Responses against Mycobacterium tuberculosis Infection","volume":"72","author":"Xue","year":"2004","journal-title":"Infect Immun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/cbr.2018.2566","article-title":"Lentivirus-based virus-like particles mediate delivery of caspase 8 into breast cancer cells and inhibit tumor growth","volume":"34","author":"Ao","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2014_1875","article-title":"Virus-like particles as vaccine","volume":"61","author":"Chroboczek","year":"2014","journal-title":"Acta Biochim Pol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-10-2569","article-title":"Stimulation of specific immune responses to simian immunodeficiency virus using chimeric hepatitis B core antigen particles","volume":"73","author":"Yon","year":"1992","journal-title":"J Gen Virol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.4.1800","article-title":"Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model","volume":"95","author":"Greenstone","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B95","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jviromet.2010.03.003","article-title":"Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis","volume":"167","author":"Krammer","year":"2010","journal-title":"J Virol Methods"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.012","article-title":"Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses","volume":"29","author":"Yin","year":"2011","journal-title":"Vaccine"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3389-1_26","article-title":"Subunit protein vaccine delivery system for tuberculosis based on hepatitis B virus core VLP (HBc-VLP) particles","volume":"1404","author":"Dhanasooraj","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S40238","article-title":"Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles","volume":"8","author":"Dhanasooraj","year":"2013","journal-title":"Int J Nanomed"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3390\/v15102123","article-title":"Nano-sized chimeric human papillomavirus-16 L1 virus-like particles displaying mycobacterium tuberculosis antigen Ag85B enhance Ag85B-specific immune responses in female C57BL\/c mice","volume":"15","author":"Zhou","year":"2023","journal-title":"Viruses"},{"key":"B103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/vaccines11010015","article-title":"Chimeric human papillomavirus-16 virus-like particles presenting P18I10 and T20 peptides from HIV-1 envelope induce HPV16 and HIV-1-specific humoral and T cell-mediated immunity in BALB\/c mice","volume":"11","author":"Chen","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.chom.2017.05.012","article-title":"Antigen availability shapes T cell differentiation and function during tuberculosis","volume":"21","author":"Moguche","year":"2017","journal-title":"Cell Host Microbe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1238649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:08:10Z","timestamp":1698944890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1238649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":105,"alternative-id":["10.3389\/fimmu.2023.1238649"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1238649","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"article-number":"1238649"}}